1. Figure 1 Flow chart diagram of high-risk group AF patients
Figure 1 Flow chart diagram of high-risk group AF patients. Loss of follow-up corresponds to those patients of whom no efficacy and safety data are available. IQR_P25–P75=interquartile range. Anticoagulant therapy=INR range (2.0–3.0). Combined therapy=triflusal 600 mg/day plus anticoagulation for an INR of 1.4–2.4.
From: Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial
Eur Heart J. 2005: doi: /eurheartj/ehi667
Eur Heart J | © The European Society of Cardiology All rights reserved. For Permissions, please

2. Figure 2 Survival curves free from vascular events (systemic embolism, stroke, myocardial infarction, sudden death, and death from bleeding) among high-risk group patients during combined antiplatelet plus anticoagulant or anticoagulant alone therapy. High risk=non-valvular with prior embolism and mitral stenosis with or without prior embolism patients. SE, standard error; n, number of cases at risk.
From: Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial
Eur Heart J. 2005: doi: /eurheartj/ehi667
Eur Heart J | © The European Society of Cardiology All rights reserved. For Permissions, please

3. Figure 4 Survival curves free from vascular events (systemic embolism, stroke, myocardial infarction, sudden death, and death from bleeding) in non-valvular with prior embolism and valvular with/without prior embolism patients during anticoagulant or combined therapy: (A) during anticoagulant alone therapy and (B) during combined therapy. SE, standard error; n, number of patients at risk; Emb, embolism.
From: Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial
Eur Heart J. 2005: doi: /eurheartj/ehi667
Eur Heart J | © The European Society of Cardiology All rights reserved. For Permissions, please

4. Figure 4 Survival curves free from vascular events (systemic embolism, stroke, myocardial infarction, sudden death, and death from bleeding) in non-valvular with prior embolism and valvular with/without prior embolism patients during anticoagulant or combined therapy: (A) during anticoagulant alone therapy and (B) during combined therapy. SE, standard error; n, number of patients at risk; Emb, embolism.
From: Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial
Eur Heart J. 2005: doi: /eurheartj/ehi667
Eur Heart J | © The European Society of Cardiology All rights reserved. For Permissions, please

5. Figure 3 Survival curves free from vascular events (systemic embolism, stroke, myocardial infarction, sudden death, and death from bleeding) in the three sub-groups of the high-risk group patients during combined or anticoagulant therapy: (A) non-valvular AF patients with prior embolism and (B) mitral stenosis patients with or without prior embolism. Emb, embolism; SE, standard error; n, number of patients at risk.
From: Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial
Eur Heart J. 2005: doi: /eurheartj/ehi667
Eur Heart J | © The European Society of Cardiology All rights reserved. For Permissions, please

6. Figure 3 Survival curves free from vascular events (systemic embolism, stroke, myocardial infarction, sudden death, and death from bleeding) in the three sub-groups of the high-risk group patients during combined or anticoagulant therapy: (A) non-valvular AF patients with prior embolism and (B) mitral stenosis patients with or without prior embolism. Emb, embolism; SE, standard error; n, number of patients at risk.
From: Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial
Eur Heart J. 2005: doi: /eurheartj/ehi667
Eur Heart J | © The European Society of Cardiology All rights reserved. For Permissions, please